Physician profile
Jason J Lyons
NPI 1083722714
$54,619.46
in general payments reported to CMS, 2019-2025
22 companies · $713 in 2025
The $713 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.52 · 2020: $18K · 2021: $21K · 2022: $4,303 · 2023: $9,956 · 2024: $218 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,100 · Food and Beverage: $1,769 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,100.00 |
| Food and Beverage | $1,769.32 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $53,511.51 | 2020-2025 | Nucala, Trelegy Ellipta |
| Electromed, INC. | $210.36 | 2023-2025 | Smartvest |
| Astrazeneca Pharmaceuticals LP | $150.85 | 2022-2025 | Breztri, Airsupra, Fasenra |
| Abbvie INC. | $125.05 | 2021 | |
| Jazz Pharmaceuticals INC. | $79.57 | 2022-2025 | |
| Grifols USA, LLC | $62.65 | 2025 | Prolastin-C Liquid |
| Astellas Pharma US INC | $48.33 | 2023-2025 | Cresemba |
| Genzyme Corporation | $47.14 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $41.07 | 2021-2023 | Dupixent |
| Janssen Pharmaceuticals, INC | $38.78 | 2019-2021 | |
| Inspire Medical Systems, INC. | $38.56 | 2023-2024 | Inspire |
| 3b Medical, INC. | $38.54 | 2025 | Luna |
| Merck Sharp & Dohme LLC | $34.76 | 2023 | |
| Amgen INC. | $31.68 | 2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $28.12 | 2023 | Glassia |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $27.59 | 2023 | |
| Harmony Biosciences LLC | $21.84 | 2024 | |
| Fisher & Paykel Healthcare INC | $20.04 | 2024 | Fisher & Paykel Healthcare |
| Teva Pharmaceuticals USA, INC. | $17.45 | 2022 | |
| Insmed, INC. | $17.38 | 2025 | Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.77 | 2024 | Ofev |
| Mylan Specialty L.P. | $13.42 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.